
Biovail gets Canadian approval for anti-depression drug CBC \|\| January 18, 2006 Biovail Corp. has won approval to market Wellbutrin XL, a drug treatment for depression in adults, the pharmaceutical company said Tuesday. The Toronto company (TSX:BVF) said Health Canada's Therapeutic Products Directorate gave the nod to the 150 mg and 300 mg tablet strengths of the once-a-day drug. Biovail aims to begin selling the drug late in the first quarter of this year. The company said the market for anti-depressants in Canada is worth about $760 million. Article Posted at www.KnowledgeDrivenRevolution.com "Once-daily Wellbutrin XL is an effective first-line treatment for depression with a low incidence of sexual dysfunction, weight gain and somnolence," said Douglas Herman, vice-president and general manager of Biovail Pharmaceuticals Canada. "This tolerability profile is important, given that drug-related side-effects of anti-depressants are a major reason why treatment may be discontinued." However, side-effects in clinical trials included headaches, insomnia, dizziness and decreased appetite, the company cautioned. Developed by Biovail in October 2001, the drug has been on the market in the United States since September 2003. Biovail said an estimated 1.4 million Canadians are affected by depression. Shares of Biovail traded down 28 cents at $30.27 in afternoon activity on the TSX. About KDR \| \| Home \| \| Weekly Features Archive	Weekly Weekly Features Archive
In Depth The Number 1 Reason YOU became a Slave Knowledge Driven Look at Your Favorite Canadian Political Parties
Archive November December January 2005 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 01 02 03 04 Weekly Features

Biovail gets Canadian approval for anti-depression drug

CBC || January 18, 2006

Biovail Corp. has won approval to market Wellbutrin XL, a drug treatment for depression in adults, the pharmaceutical company said Tuesday.

The Toronto company (TSX:BVF) said Health Canada's Therapeutic Products Directorate gave the nod to the 150 mg and 300 mg tablet strengths of the once-a-day drug.

Biovail aims to begin selling the drug late in the first quarter of this year.

The company said the market for anti-depressants in Canada is worth about $760 million.

Article Posted at www.KnowledgeDrivenRevolution.com

"Once-daily Wellbutrin XL is an effective first-line treatment for depression with a low incidence of sexual dysfunction, weight gain and somnolence," said Douglas Herman, vice-president and general manager of Biovail Pharmaceuticals Canada.

"This tolerability profile is important, given that drug-related side-effects of anti-depressants are a major reason why treatment may be discontinued."

However, side-effects in clinical trials included headaches, insomnia, dizziness and decreased appetite, the company cautioned.

Developed by Biovail in October 2001, the drug has been on the market in the United States since September 2003. Biovail said an estimated 1.4 million Canadians are affected by depression.

Shares of Biovail traded down 28 cents at $30.27 in afternoon activity on the TSX.

About KDR | | Home | | Weekly Features Archive

Weekly

Chicken Little Terrorist: Creating Fake Terrorists

Weekly Features Archive

In Depth

The Number 1 Reason YOU became a Slave

Knowledge Driven Look at Your Favorite Canadian Political Parties